Overview

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Chiauranib